About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Novel Antibody Targeting Fat-Tissue Hormone May Lead To Type 2 Diabetes Treatment

by Shirley Johanna on January 4, 2016 at 4:19 PM
Font : A-A+

Novel Antibody Targeting Fat-Tissue Hormone May Lead To Type 2 Diabetes Treatment

An anti-body developed by researchers to target a hormone in adipose tissue can be a potential new treatment for diabetes, says a new study.

Besides Type-2 diabetes, the new therapeutic that improves glucose regulation and reduces fatty liver could potentially be used to treat fatty liver disease, and other metabolic diseases, the study said.

Advertisement


These monoclonal antibodies have the potential to be transformative first-in-class therapeutics to fight obesity-related metabolic and immunometabolic disease, the researchers said.

The hormone in fat tissue that the antibody targets is called aP2 (also known as FABP4).

"The importance of this study is two-fold: first, demonstrating the importance of aP2 as a critical hormone in abnormal glucose metabolism, and secondly, showing that aP2 can be effectively targeted to treat diabetes and potentially other immunometabolic diseases," said Gokhan Hotamisligil, professor at Harvard T.H. Chan School of Public Health.
Advertisement

The increase in adipose tissue characteristic of obesity has long been linked to increased risk for metabolic diseases such as Type-2 diabetes and cardiovascular disease.

Recently, it has become clear that the tissue itself plays an active role in metabolic disease, in part by releasing hormones which act in distant sites such as the liver, muscle, and brain that affect systemic metabolism.

In the new study, the researchers described the development and evaluation of novel monoclonal antibodies targeting the hormone aP2.

The team found that one of these antibodies effectively improved glucose regulation in two independent models of obesity.

Additionally, beneficial reductions in liver fat were observed.

This work is still at the pre-clinical stage and will require extensive evaluation for safety and effectiveness before being considered for use in humans, the researchers pointed out.

The findings were detailed online in the journal Science Translational Medicine.

Source: IANS
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
World Heart Day in 2022- Use Heart for Every Heart
Anemia among Indian Women and Children Remains a Cause of Concern- National Family Health Survey-5
H1N1 Influenza Prevention in Children: What Parents Need to Know
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Diabetic Retinopathy Diabetes Diabetic Diet Otitis Media Diabetes - Essentials Diabetes - Self-Monitoring of Blood Glucose (SMBG) Insulin Delivery Devices Diabetes and Exercise Stress Relief Through Alternative Medicine Stress and the Gender Divide 

Most Popular on Medindia

Sanatogen Loram (2 mg) (Lorazepam) Diaphragmatic Hernia Blood - Sugar Chart A-Z Drug Brands in India Find a Doctor Daily Calorie Requirements Hearing Loss Calculator The Essence of Yoga Calculate Ideal Weight for Infants
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Novel Antibody Targeting Fat-Tissue Hormone May Lead To Type 2 Diabetes Treatment Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests